Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic plaque psoriasis with disease duration of at least 6 months~* Sub-optimal response to treatment with etanercept, methotrexate, or narrow-band UVB phototherapy~Exclusion Criteria:~* Prior treatment with adalimumab~* Multiple concomitant therapy restrictions and/or washouts (topicals, ultraviolet, other systemic psoriasis therapies)~* Prior treatment with natalizumab~* Concurrent active skin diseases/infections~* Poorly controlled medical conditions~* History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease~* History of certain cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).